Recent Congress Publications
For Boehringer Ingelheim, cancer care is personal – today and for future generations. Our long-term commitment to oncology is to pursue leading science to develop innovative cancer treatments across different tumor types.
Page last updated: October 2026
ESMO 2026
Subgroup analysis of the ongoing Phase Ib DAREON®-7 study: Outcomes with first-line obrixtamig plus standard of care in neuroendocrine carcinomas by DLL3 expression status
Author(s): Capdevila et al.
DAREON®-NEC-1: Phase III trial of first-line (1L) obrixtamig plus carboplatin and etoposide (SoC) vs SoC in patients with delta-like ligand 3 (DLL3)-positive extrapulmonary neuroendocrine carcinoma (epNEC)
Author(s): Vandamme et al.
DAREON®-9: A Phase Ib open-label dose escalation/confirmation study of obrixtamig (BI 764532) plus topotecan in patients with extensive-stage small cell lung cancer (ES-SCLC) ‒ topotecan use analysis
Author(s): Wermke et al.
Updated Phase Ia results with systemic STING agonist BI 1703880 plus ezabenlimab in patients with advanced solid tumors
Author(s): Harrington et al.
WCLC 2026
DAREON®-Lung-1: Phase III trial of first-line obrixtamig plus standard of care (atezolizumab, carboplatin, and etoposide) versus standard of care in ES-SCLC
Author(s): Leal et al.
ASCO 2026
Analysis of delta-like ligand 3 (DLL3) expression levels and characteristics of patients with advanced extrapulmonary neuroendocrine carcinomas (epNECs) from an ongoing Phase I trial
Author(s): Gambardella et al.
DAREON®-8: updated efficacy and safety from a Phase I dose-escalation/expansion trial of first-line obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma
Author(s): Peters et al.
ELCC 2026
A Phase I dose escalation trial of obrixtamig + ezabenlimab in patients with small cell lung cancer (SCLC) or other neuroendocrine carcinomas (NECs) expressing DLL3
Author(s): Mazières et al.
ENETS 2026
DAREON®-7: Phase I open-label dose-escalation/expansion study of first-line obrixtamig (BI 764532) plus platinum-doublet chemotherapy in patients with DLL3-positive neuroendocrine carcinomas
Author(s): Capdevila et al.
ASCO GU 2026
Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas of genitourinary origin with high or low DLL3 expression: results from an ongoing Phase I trial
Author(s): Navarro-Gorro et al.
NANETS 2025
DAREON®-7: Phase I open-label dose-escalation/-expansion study of first-line obrixtamig (BI 764532) plus platinum-doublet chemotherapy in patients with DLL3-positive neuroendocrine carcinomas
Author(s): Chauhan et al.
